Novocure stock advanced Wednesday morning — but pulled back from more massive gains — after the Food and Drug Administration ...

5 analysts have shared their evaluations of NovoCure NVCR during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic cancer study met its endpoints. The PANOVA-3 study (NCT03377491) met its ...

Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough.

Piper Sandler raised the firm’s price target on Novocure (NVCR) to $42 from $28 and keeps an Overweight rating on the shares. The firm thinks the catalyst path for Novocure shares screens more ...

From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for ...

BAAR, Switzerland, January 03, 2025--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday ...

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on NovoCure (NVCR – Research Report) today and set a price target of $30.00. Don't Miss our Black Friday Offers: Unlock your ...

Evercore ISI raised the firm’s price target on Novocure (NVCR) to $46 from $34 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science Tools and ...